Core Viewpoint - The company plans to use part of the surplus raised funds for other investment projects and to postpone certain investment projects, which aligns with its strategic development and aims to enhance the efficiency of fund utilization [1][10][11]. Fundraising Basic Situation - The company raised a net amount of RMB 800.48 million from its initial public offering of 34,020,000 shares, with all funds accounted for and managed in a dedicated account [1][2]. - The funds were subject to strict regulatory oversight as per relevant guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][10]. Investment Project Situation - Due to the net amount raised being lower than initially planned, the company adjusted the investment amounts for its projects to ensure efficient use of funds [2][5]. - The company has terminated certain projects, including the "In Vitro Diagnostic Product R&D and Industrialization Project (Phase I)" as of April 2024, and has made adjustments to other projects [2][5][9]. Use of Surplus Funds - The company intends to allocate RMB 60 million of the surplus funds towards the "In Vitro Diagnostic Product R&D Project," focusing on international market expansion and collaboration with Quanterix Corporation for advanced detection technologies [5][9]. - The surplus funds will also support the development of products for the EU IVDR and US FDA markets, enhancing the company's competitive position [5][9]. Project Postponement - The timeline for the "In Vitro Diagnostic Product R&D Project" has been extended from October 2025 to April 2027 to accommodate the current progress and ensure effective fund utilization [9][10]. Impact on the Company - The adjustments made in the use of surplus funds and project timelines are expected to optimize resource allocation and enhance operational efficiency without adversely affecting the company's core business [9][10]. Review and Decision Procedures - The company’s board and supervisory committee have approved the use of surplus funds, which will be submitted for shareholder approval, ensuring compliance with regulatory requirements [10][11].

Core Viewpoint - The company has decided to utilize part of the remaining raised funds for other investment projects and to extend the timeline for the "in vitro diagnostic product R&D project" by 18 months, from October 2025 to April 2027 [1][3][9]. Fundraising Overview - The company raised a total of RMB 886.56 million (approximately USD 126.5 million) through its initial public offering, with a net amount of RMB 800.48 million (approximately USD 115.5 million) after deducting issuance costs [1][2]. - The funds are managed in a dedicated account as per regulations, and the company has signed a storage supervision agreement with the sponsor and the bank [2]. Investment Project Adjustments - Due to the net amount raised being lower than initially planned, the company adjusted the investment amounts for various projects to ensure efficient use of funds [2]. - The company plans to invest RMB 60 million (approximately USD 8.6 million) of the remaining funds into the "in vitro diagnostic product R&D project" [3][5]. Project Timeline Extension - The timeline for the "in vitro diagnostic product R&D project" has been extended by 18 months, now set to reach a usable state by April 2027 [3][9]. - This project includes research and development of new products and foundational technology for various diagnostic platforms [9]. Strategic Focus - The company aims to enhance its international market presence, particularly in Southeast Asia, and is accelerating clinical trials and submissions for EU IVDR and US FDA products [5][9]. - A strategic partnership with Quanterix Corporation has been established to introduce advanced single-molecule detection technology, focusing on developing products related to neurological biomarkers [5][9]. Decision-Making Process - The decision to use part of the remaining funds and extend project timelines was approved by the company's board and supervisory committee, and it will be submitted for shareholder approval [10][11]. - The supervisory committee and the sponsor have expressed their agreement with the adjustments, confirming compliance with relevant regulations [11][12].

Summary of Key Points Core Viewpoint - The company has decided to change the funding method for certain investment projects from providing loans to its subsidiary to increasing capital in the subsidiary, utilizing its own funds for this purpose [1][7][10]. Group 1: Fundraising Overview - The company raised a total of RMB 1,216,511,427.60 through its initial public offering, with a net amount of RMB 1,110,744,306.58 after deducting issuance costs [1][5]. - The funds were deposited into a special account approved by the company's board of directors, and a tripartite supervision agreement was signed with the sponsor and the commercial bank [1][8]. Group 2: Investment Project Details - The net amount raised will be allocated to various investment projects, including a high-end pharmaceutical product project and a pharmaceutical intermediate project [5][6]. - The company plans to invest RMB 43,886.66 million in the pharmaceutical intermediate project, with a portion of this amount being changed from a loan to a capital increase [6][7]. Group 3: Capital Increase Implementation - The company will increase its investment in its wholly-owned subsidiary, Jin Kai Pharmaceutical, by RMB 32,886.66 million and an additional RMB 1,913.34 million from its own funds [6][7]. - Following this capital increase, the registered capital of Jin Kai Pharmaceutical will rise from RMB 15,000.00 million to RMB 49,800.00 million [6][7]. Group 4: Management and Oversight - The company has established a special account for the management of raised funds and will adhere to relevant regulations to ensure the safety of these funds [8][10]. - The board of directors and the supervisory board have both approved the change in funding method, affirming that it aligns with legal requirements and benefits the company's long-term development [10][11].

Group 1 - The company held its seventh supervisory board's fifth meeting on August 20, 2025, which was conducted via telecommunication and was attended by all supervisory members and executives [2][4]. - The supervisory board unanimously agreed to reduce the investment scale of certain fundraising projects, conclude some fundraising projects, and permanently supplement the remaining raised funds into working capital [3][4]. - The decision to reduce the investment scale and conclude projects is based on the company's current situation and aims to improve the efficiency of fund usage and lower financial costs, benefiting the company and all shareholders, particularly minority shareholders [2][3]. Group 2 - The meeting was legally valid and complied with the Company Law of the People's Republic of China and the company's articles of association [2]. - The company will publish detailed information regarding the reduction of fundraising investment scale and the conclusion of projects in major financial newspapers and platforms [3][4].

Core Viewpoint - The company, Megachip New Materials Technology (Shanghai) Co., Ltd., is changing the implementation method of part of its fundraising projects and adjusting its internal investment structure to enhance operational efficiency and marketing effectiveness [5][8]. Fundraising Overview - The company successfully issued 27,000,000 shares at a price of RMB 58.08 per share, raising a total of RMB 1,568,160,000. After deducting underwriting fees and other expenses, the net amount raised was RMB 1,433,768,189.41, with actual funds received amounting to RMB 1,453,525,120 [2][4]. Project Investment Plans - The planned investment projects include: - New annual production of 70,000 tons of high-performance coatings: RMB 43,000,000 - Headquarters and R&D center in Jiading: RMB 15,000,000 - Intelligent warehousing construction: RMB 5,553,470 - Marketing and service network construction: RMB 4,205,510 - Supplementing working capital: RMB 25,000,000 - Total planned investment: RMB 92,758,980 [4][5]. Changes in Project Implementation - The company plans to change the implementation method of the "Marketing and Service Network Construction Project" by canceling domestic and overseas site expenses and equipment purchases, while increasing personnel and travel expenses [6][7]. - The project will focus on establishing regional sales service teams at the headquarters and subsidiary in Zhuhai, rather than setting up fixed marketing points in various regions [6][7]. Reasons for Adjustments - The adjustments are made to improve efficiency and flexibility in marketing and service operations, as the previous plan of establishing fixed points was found to be limiting [6][7]. - The company will utilize its own funds for overseas sales activities instead of relying on raised funds due to challenges in cross-border payments and regulatory compliance [7]. Impact of Changes - The changes do not alter the total amount of fundraising or the intended use of funds, ensuring that shareholder interests are not compromised [8][9]. - The adjustments are expected to enhance the efficiency of fund usage and align with the company's strategic development goals [8][9]. Approval Process - The adjustments were approved by the company's board on August 20, 2025, and will be submitted for shareholder approval [9]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has reviewed the changes and found them compliant with relevant regulations, confirming that the adjustments will not affect the normal execution of the fundraising investment plan [9].

Core Viewpoint - The company, Shenzhen Aoya Design Co., Ltd., is temporarily adjusting the use of part of the fundraising project sites to enhance asset efficiency and align with business development needs [6][9][10]. Fundraising Overview - The company raised a total of RMB 813.45 million through its initial public offering, with a net amount of RMB 714.59 million after deducting issuance costs [1][2]. - The funds are primarily allocated to several projects, including the construction of a service network and a technology research and development center [2][3]. Fund Usage Status - As of July 30, 2025, the company has invested RMB 539.80 million, which is 75.54% of the net funds raised [4]. - The technology research and development center expansion project has seen an investment progress of 88.74%, while the information technology and collaboration platform project has a completion rate of 29.28% [3][4]. Adjustment of Project Sites - The company has decided to temporarily adjust the use of part of the fundraising project sites, specifically leasing out idle properties in Haikou to improve asset utilization [6][9]. - This decision aligns with the company's strategy to enhance operational efficiency without altering the intended use of the raised funds [9][10]. Approval Process - The adjustment was approved by the company's board of directors and independent directors, confirming compliance with relevant regulations and ensuring no harm to shareholder interests [10][11].

Core Viewpoint - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss two main proposals: changing the implementation subjects and locations of certain fundraising projects, and expanding the company's business scope while amending its articles of association [1][13]. Group 1: Proposal on Changing Implementation Subjects and Locations - The company plans to change the implementation subjects and locations of certain fundraising projects to enhance the efficiency of fund usage and align with its strategic planning and business needs [6][10]. - The total investment amount for the fundraising projects will remain unchanged, and there will be no adverse impact on the fundraising projects or shareholder interests [12]. - The new implementation subject will be Xigao Institute (Xiamen) Electric Research Institute Co., Ltd., which is positioned as a new R&D institution with testing service capabilities [11][12]. Group 2: Proposal on Expanding Business Scope and Amending Articles of Association - The company intends to expand its business scope to include manufacturing and sales of testing machines and experimental analysis instruments, among other activities [13][14]. - The amendments to the articles of association will reflect the expanded business scope, ensuring compliance with regulatory requirements [15]. - The company seeks authorization from the shareholders to handle the necessary business registration changes related to the amendments [15].

Core Viewpoint - The company plans to adjust and postpone certain sub-projects within its fundraising investment project for drug research and development, while maintaining the total investment amount for the "Drug Research and Development Project" unchanged [1][2][3] Fundraising Investment Project Overview - The company raised a total of RMB 724.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related expenses [1][2] - As of May 31, 2025, the cumulative investment from the raised funds amounted to RMB 408.36 million [2] Adjustments and Postponements - The adjustments involve reallocating unspent funds from completed projects to ongoing or new projects, optimizing the priority of funding based on market conditions and research progress [4][5] - The company aims to enhance the efficiency of fund usage while ensuring that the total investment in the "Drug Research and Development Project" remains unchanged [3][4] Specific Adjustments - Funds from completed projects such as "Compound Polyethylene Glycol Electrolyte Powder" and others will be redirected to ongoing projects like "Qianqing Granules" and new investment projects [5][6] - The company will extend the research timelines for projects like "Qianqing Granules" and "L-Carnitine Oral Solution" to the end of 2028, adjusting funding allocations accordingly [6][8] Research and Development Focus - The company continues to focus on projects in the digestive, respiratory, and anti-infection fields, while also expanding into pain relief, cardiovascular, neurological, and lymphatic treatment areas [8][9] - A total of RMB 47.6 million is allocated for respiratory products, and RMB 47.8 million for pain relief products, among other therapeutic areas [9][10][12] Feasibility Analysis - The company's drug research capabilities and a strong core research team support the ongoing implementation of projects, ensuring a robust pipeline for future product development [15][16] - The adjustments are made to align with market demands and the company's strategic planning, without negatively impacting normal operations or shareholder interests [17][18]

Group 1 - The company held its fourth supervisory board meeting on June 5, 2025, with all three supervisors present, complying with legal and regulatory requirements [1][2] - The supervisory board approved the proposal to terminate the data science center project and permanently allocate the remaining raised funds to supplement working capital, with a unanimous vote of 3 in favor [1][2] - The decision to terminate the project was made based on the company's actual situation and long-term development plan, aiming to improve the efficiency of fund utilization and align with the interests of the company and its shareholders [2]

江西国科军工集团股份有限公司（以下简称"公司"）于2025年3月24日召 开第三届董事会第十五次会议、第三届监事会第十五次会议，审议通过了《关于 调整部分募投项目内部投资结构的议案》，同意公司在募投项目总额不变的前提 下，对首次公开发行募集资金投资项目"统筹规划建设项目"内部投资结构进行 调整，公司监事会发表了明确的同意意见，保荐机构国泰君安证券股份有限公司 （以下简称"保荐机构"）对公司出具了明确的核查意见。 一、募集资金基本情况 国科军工: 关于调整部分募投项目内部投资结构的 公告 证券代码：688543 证券简称：国科军工 公告编号：2025-019 江西国科军工集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经中国证券监督管理委员会证监许可［2023］1011 号文《关于同意江西国科 军工集团股份有限公司首次公开发行股票注册的批复》的核准，公司采用向社会 公开发行人民币普通股（A 股）3667 万股，发行价格为每股 43.67 元。截止 2023 年 6 月 16 日，本公司实际已向社会公开发行人 ...